Italia markets closed

Roche Holding AG (0QOK.IL)

IOB - IOB Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
315,65+2,75 (+0,88%)
Alla chiusura: 06:28PM BST
Schermo intero
Chiusura precedente312,90
Aperto316,00
Denaro307,80 x N/D
Lettera323,50 x N/D
Min-Max giorno314,55 - 318,85
Intervallo di 52 settimane298,60 - 650,25
Volume433.916
Media Volume407.797
Capitalizzazione261,976B
Beta (5 anni mensile)0,29
Rapporto PE (ttm)17,84
EPS (ttm)17,69
Prossima data utiliN/D
Rendimento e dividendo (forward)9,30 (2,97%)
Data ex dividendo17 mar 2022
Stima target 1AN/D
  • GlobeNewswire

    Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2

    Elecsys IGRA SARS-CoV-2 test supports the better understanding of immune response to SARS-CoV-2 infection or vaccinationThe test detects T-cell response, which may play an important role in determining if immune protection has been achievedThe new diagnostic test may provide clinical care guidance, particularly for immunocompromised and high-risk patient groups Basel, 15 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys® IGRA SARS-CoV-2 test in countries

  • GlobeNewswire

    Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older

    Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age The FDA also approved Xofluza to prevent influenza in children aged five years and older following contact with an infected person Basel, 12 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (balo

  • GlobeNewswire

    Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results

    IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung cancerAdministered under the skin, the subcutaneous formulation reduces time spent receiving treatment to just minutes, compared with up to an hour for IV infusionData will be submitted to health authorities globally, including the US Food and Drug Administration and European Medicines Agency Basel,